Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma

A 12 Week, Multi-center,Randomized, Double Blinded, Parallel Group, Placebo-controlled, 4-arm, Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00936624

Enrollment

245

Registered

2009-07-10

Start date

2009-07-31

Completion date

2011-05-31

Last updated

2013-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Persistent asthma

Brief summary

This study is a dose finding trial to assess the efficacy and safety of SOTB07 in persistent asthma.

Detailed description

A 12 week, Multi-center, Randomized, Double blinded, Parallel group, Placebo-controlled, 4-arm, Dose finding trial to Assess the Efficacy and Safety of SOTB07 in persistent asthma.

Interventions

DRUGSOTB07

SOTB07 100mg

DRUGplacebo

placebo

DRUGmontelukast

montelukast 10mg po, bid, 12week

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male or eligible female subjects aged 15 years or more 2. A female is eligible if she is of: * Non-child bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is at least 2 year after post- menopausal * Child bearing potential and agrees to the acceptable contraceptive methods used consistently and correctly * Negative pregnancy test at screening 3. Non-smoker for at least 1 year, a pack history of ≤ 10 pack years 4. Symptom of persistent asthma, as defined by the National Institute of Health (NIH) 5. 50% ≤ FEV1 ≤ 85% predicted at screening visit (withholding inhaled, short acting ß-agonist for 6 hours) 6. FEV1 reversibility ≥ 12% and 200 ml at 20-30 minutes after inhalation of a short acting ß-agonist (Salbutamol 2 puffs; 200㎍) at Visit 1 or within 6 months before Visit 1 7. Capable of withholding salbutamol use for ≥ 6 hours prior to clinic visits 8. Appropriately signed and dated informed consent has been obtained

Exclusion criteria

1. Active upper or lower respiratory tract infection within 3 weeks before visit 1 2. Emergency room treatment for asthma within 1 month or hospitalization for asthma within 3 months before visit 1 3. Any evidence of infectious, oncologic, or other active pulmonary disease obtained by chest radiography within 12 months before visit 1 4. Clinically significant, in the opinion of the investigator, hematological, liver, renal, heart, neurological disease, or other serious disease 5. Hypersensitivity to any β2-agonist, sympathomimetic drug, leukotriene receptor antagonist or Sophora tonkinensis Radix Rhizoma 6. Clinically significant and uncontrolled psychiatric disease or history of drug or alcohol abuse 7. Inhaled, oral or parenteral corticosteroids within 4 weeks before visit 1 8. Change of Immunotherapy within 6 months before visit 1 9. Administration of the antiasthma agent within 1 week of visit 1 10. Administration of any other medication which may affect the course of asthma, or interact with sympathomimetic amines 11. Participation in study using an experimental medication within 1 month before visit 1 12. Other ineligible subject in the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
% change from baseline for FEV1 at each visit	12 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026